Crestline Management’s BioNTech BNTX Stock Holding History

Crestline Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,272	Closed	-$943K	–	83
2024 Q4	$943K	Buy	+8,272	New	+$944K	0.03%	427

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Crestline Management's BNTX Position: Q1 2025 in Review

Crestline Management sold out of BioNTech (BNTX) in Q1 2025, closing a stake of 8,272 shares — an estimated $943K sold.

Crestline Management first reported a position in BNTX in Q4 2024 and held it in 1 quarter. The position peaked at $943K in Q4 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

Crestline Management reported no remaining BioNTech position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 8,272 BioNTech shares in Q1 2025, an estimated $943K.
Crestline Management first reported a position in BioNTech in Q4 2024 and held it in 1 quarter.
Crestline Management's BioNTech position peaked at $943K in Q4 2024.
280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.